Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 42 5-Year Yield-on-Cost % is 5.79 as of Aug. 16, 2026, which is 29% above its 10-year median of 4.48. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 317 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 81.07% on this metric.
Weleader Biomedical Co's yield on cost for the quarter that ended in Mar. 2026 was 5.79.
The historical rank and industry rank for Weleader Biomedical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:7713'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.77 Med: 4.48 Max: 11.15
Current: 5.79
During the past 6 years, Weleader Biomedical Co's highest Yield on Cost was 11.15. The lowest was 2.77. And the median was 4.48.
ROCO:7713's 5-Year Yield-on-Cost % is ranked better than 81.07% of 317
companies
in the Medical Devices & Instruments industry
Industry Median: 2.29
vs ROCO:7713: 5.79
Weleader Biomedical Co (ROCO:7713) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Weleader Biomedical Co 5-Year Yield-on-Cost % Related Terms
ROCO:7713 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's 5-Year Yield-on-Cost % falls into.
Weleader Biomedical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Weleader Biomedical Co (ROCO:7713) has a 5-Year Yield-on-Cost % of 5.79 as of Aug. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Weleader Biomedical Co and its competitors. This is 29% above median its historical median of 4.48. Over the past decade, Weleader Biomedical Co's 5-Year Yield-on-Cost % has ranged from 2.77 to 11.15. According to the industry distribution chart, Weleader Biomedical Co ranks #60 out of 317 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Weleader Biomedical Co's 5-Year Yield-on-Cost % too high?
Weleader Biomedical Co's current 5-Year Yield-on-Cost % of 5.79 is 29% above median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 2.77 to a high of 11.15. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.29. Weleader Biomedical Co's value of 5.79 is 152.8% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #60 out of 317 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #60 out of 317 companies for 5-Year Yield-on-Cost %. This places Weleader Biomedical Co in the top 19% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Weleader Biomedical Co's value of 5.79 is 152.8% above this benchmark. Historically, Weleader Biomedical Co's own 5-Year Yield-on-Cost % has ranged from 2.77 to 11.15 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 2.29, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.29, based on 317 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current 5-Year Yield-on-Cost % of 5.79 is 152.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current 5-Year Yield-on-Cost % is 5.79, which is 29% above median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current 5-Year Yield-on-Cost % of 5.79. The current 5-Year Yield-on-Cost % is 5.79, which is 29% above median its 10-year median of 4.48 and 152.8% above the Medical Devices & Instruments industry median of 2.29. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current 5-Year Yield-on-Cost % is 5.79 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score
Get the complete analysis for ROCO:7713
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
